About Vaxart


Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform.

We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise.

Our Mission


From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases.

We are dedicated to advancing vaccine science to create safe, effective, and accessible solutions that protect communities worldwide and empower people to lead healthier lives.

Our Science


Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology.

VAXART News


  • Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

    Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

    Read More

  • Vaxart to Host Upcoming Conference Calls

    Vaxart to Host Upcoming Conference Calls

    Read More

  • Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

    Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

    Read More